Press Release

Media Contact
Martin Kunze
T +49 6172 609-2115
martin.kunze@fresenius.com
Contact for analysts andinvestors
Dr. Dominik Heger
T +49 6172 609-2601
dominik.heger@fmc-ag.com
www.freseniusmedicalcare.com

July 30, 2018

Fresenius Medical Care achieves preclinical milestone in
its regenerative medicine program for chronic kidneydiseaseFresenius Medical Care, the world’s largest provider of dialysis products and services,announced today that its subsidiary Unicyte AG has achieved a key preclinical milestone
in its regenerative medicine program for chronic kidney disease. The company was able
to confirm a disease modifying potential for its proprietary nano-Extracellular Vesicles(“nEVs” are stem cell-derived particles that support communication between cells) in asecond preclinical model of chronic kidney disease.
When administered to mice with fast progressing kidney disease, Unicyte’s nEVs
prevented renal fibrosis, a hallmark of chronic kidney disease. In particular, nEVs
significantly reduced interstitial fibrosis and tubular necrosis while also inhibiting
infiltration of various cells. This resulted in near-to-normal recovery of kidney function.
The study conducted in collaboration with Prof. Giovanni Camussi of the University ofTurin, Italy, has been accepted for publication in the peer-reviewed journal Frontiers ofImmunology (https://doi.org/10.3389/fimmu.2018.01639).
These new results support previous findings in a preclinical model of slowly progressing
kidney disease (diabetic nephropathy), a major pathology that often leads to end-stage
renal disease. Combined results of these studies demonstrate the efficacy and theunderlying mechanism of action of nEVs in preventing renal fibrosis and subsequent
Page 1/2

progression to end-stage renal disease. Unicyte will continue the preclinical and clinicaldevelopment of its proprietary nEVs for treatment of chronic and acute kidney diseases.
Dr. Olaf Schermeier, Fresenius Medical Care’s CEO for Global Research and Development,
said: “We are very excited about the progress we have made with our research anddevelopment activities over the last 30 months since we have established Unicyte. Basedon these achievements, Unicyte will continue to explore the potential of nEVs for thetreatment of patients in pre-dialysis stages of chronic kidney disease.”
Prof. Giovanni Camussi, Professor Emeritus at the University of Turin and Member ofUnicyte’s Scientific Advisory Board, said, “nEVs are a promising regenerative medicine
technology platform. Our aim is to develop new and better treatment options for severely
and chronically ill patients over time. Achieving this preclinical milestone represents animportant step towards testing nEVs in the clinical setting.”
With multiple therapeutic programs at the clinical and preclinical stage, Unicyte has
established a broad pipeline in kidney and liver diseases, diabetes and oncology. The
company is seeking strategic partnerships for its non-renal programs.

Fresenius Medical Care is the world's largest provider of products and services for individuals
with renal diseases of which around 3.2 million patients worldwide regularly undergo dialysis
treatment. Through its network of 3,790 dialysis clinics, Fresenius Medical Care provides dialysis
treatments for 322,253 patients around the globe. Fresenius Medical Care is also the leading
provider of dialysis products such as dialysis machines or dialyzers. Along with its core business,the company provides related medical services in the field of Care Coordination. Fresenius MedicalCare is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company’s website at www.freseniusmedicalcare.com.
Unicyte AG is a regenerative medicine company with a focus on kidney & liver disorders, diabetes
and oncology. Unicyte evolved from a long-term research collaboration of Italy’s University of Turinand Fresenius Medical Care. Unicyte is headquarted in Oberdorf NW, Switzerland, and is anindependent affiliate of Fresenius Medical Care, the world's largest provider of products andservices for individuals with renal diseases.
For more information visit the company’s website at www.unicyte.ch.
Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual
results could differ materially from those described in these forward-looking statements due to certain factors,
including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate
fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These andother risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S.
Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any
responsibility to update the forward-looking statements in this release.

Page 2/2